JP2017507655A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017507655A5 JP2017507655A5 JP2016553630A JP2016553630A JP2017507655A5 JP 2017507655 A5 JP2017507655 A5 JP 2017507655A5 JP 2016553630 A JP2016553630 A JP 2016553630A JP 2016553630 A JP2016553630 A JP 2016553630A JP 2017507655 A5 JP2017507655 A5 JP 2017507655A5
- Authority
- JP
- Japan
- Prior art keywords
- cdkl5
- fusion protein
- polypeptide
- protein
- tatk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019220178A JP6896050B2 (ja) | 2014-02-28 | 2019-12-05 | ＴＡＴｋ−ＣＤＫＬ５融合タンパク質、組成物、製剤、及びそれらの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461946280P | 2014-02-28 | 2014-02-28 | |
| US61/946,280 | 2014-02-28 | ||
| PCT/IB2015/000999 WO2015128746A2 (en) | 2014-02-28 | 2015-02-27 | Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019220178A Division JP6896050B2 (ja) | 2014-02-28 | 2019-12-05 | ＴＡＴｋ−ＣＤＫＬ５融合タンパク質、組成物、製剤、及びそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017507655A JP2017507655A (ja) | 2017-03-23 |
| JP2017507655A5 true JP2017507655A5 (https=) | 2019-08-22 |
| JP6629747B2 JP6629747B2 (ja) | 2020-01-15 |
Family
ID=53539745
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016553630A Active JP6629747B2 (ja) | 2014-02-28 | 2015-02-27 | ＴＡＴｋ−ＣＤＫＬ５融合タンパク質、組成物、製剤、及びそれらの使用 |
| JP2019220178A Active JP6896050B2 (ja) | 2014-02-28 | 2019-12-05 | ＴＡＴｋ−ＣＤＫＬ５融合タンパク質、組成物、製剤、及びそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019220178A Active JP6896050B2 (ja) | 2014-02-28 | 2019-12-05 | ＴＡＴｋ−ＣＤＫＬ５融合タンパク質、組成物、製剤、及びそれらの使用 |
Country Status (33)
| Country | Link |
|---|---|
| US (4) | US9290746B2 (https=) |
| EP (2) | EP3110837B1 (https=) |
| JP (2) | JP6629747B2 (https=) |
| KR (1) | KR102307276B1 (https=) |
| CN (1) | CN106255706A (https=) |
| AU (2) | AU2015221860B2 (https=) |
| BR (1) | BR112016019868B1 (https=) |
| CA (1) | CA2940401C (https=) |
| CL (1) | CL2016002142A1 (https=) |
| CR (1) | CR20160392A (https=) |
| CY (2) | CY1122644T1 (https=) |
| DK (2) | DK3608334T3 (https=) |
| DO (1) | DOP2016000220A (https=) |
| EA (2) | EA038000B1 (https=) |
| ES (2) | ES2745335T3 (https=) |
| HR (2) | HRP20191511T1 (https=) |
| HU (2) | HUE055282T2 (https=) |
| IL (2) | IL247481B (https=) |
| LT (2) | LT3608334T (https=) |
| MX (2) | MX2016011167A (https=) |
| MY (1) | MY181566A (https=) |
| NI (1) | NI201600127A (https=) |
| PE (1) | PE20161406A1 (https=) |
| PH (1) | PH12016501689A1 (https=) |
| PL (2) | PL3608334T3 (https=) |
| PT (2) | PT3110837T (https=) |
| RS (2) | RS59344B1 (https=) |
| SG (2) | SG10202000537RA (https=) |
| SI (2) | SI3110837T1 (https=) |
| SM (2) | SMT202100478T1 (https=) |
| SV (1) | SV2016005264A (https=) |
| WO (1) | WO2015128746A2 (https=) |
| ZA (2) | ZA201606655B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106255706A (zh) * | 2014-02-28 | 2016-12-21 | 万校之母-博洛尼亚大学 | TATk‑CDKL5融合蛋白、其组合物、配制品以及用途 |
| US20210268072A1 (en) * | 2016-06-28 | 2021-09-02 | Alma Mater Studiorum - Universitá Di Bologna | TATk-CDKL5 Fusion Proteins, Compositions, Formulations, and Use Thereof |
| JP2021505135A (ja) * | 2017-11-30 | 2021-02-18 | アミカス セラピューティックス インコーポレイテッド | Ｃｄｋｌ５発現変異体及びｃｄｋｌ５融合タンパク質 |
| CA3150224A1 (en) | 2019-09-10 | 2021-03-18 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| CA3156506A1 (en) * | 2019-10-30 | 2021-05-06 | Amicus Therapeutics, Inc. | Recombinant cdkl5 proteins, gene therapy and production methods |
| IT202000025423A1 (it) * | 2020-10-27 | 2022-04-27 | Ulisse Biomed S P A | Uso di proteine per il trattamento di patologie associate a tossine formanti pori o a proteine virali |
| KR20230128001A (ko) | 2020-12-01 | 2023-09-01 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 엔젤만 증후군의 치료를 위한 조성물 및 이의 용도 |
| EP4387641A4 (en) * | 2021-08-18 | 2025-07-09 | Ultragenyx Pharmaceutical Inc | RECOMBINANT AAV FORMULATIONS |
| WO2025050032A1 (en) * | 2023-08-31 | 2025-03-06 | Ultragenyx Pharmaceutical Inc. | Methods of producing cdkl5 proteins and uses of the same |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011322715A1 (en) * | 2010-10-25 | 2013-05-23 | Centre National De La Recherche Scientifique | Treatment of MeCP2-associated disorders |
| CN106255706A (zh) * | 2014-02-28 | 2016-12-21 | 万校之母-博洛尼亚大学 | TATk‑CDKL5融合蛋白、其组合物、配制品以及用途 |
-
2015
- 2015-02-27 CN CN201580010858.9A patent/CN106255706A/zh active Pending
- 2015-02-27 MX MX2016011167A patent/MX2016011167A/es active IP Right Grant
- 2015-02-27 MX MX2020001223A patent/MX392778B/es unknown
- 2015-02-27 PL PL19179287T patent/PL3608334T3/pl unknown
- 2015-02-27 KR KR1020167026521A patent/KR102307276B1/ko active Active
- 2015-02-27 SM SM20210478T patent/SMT202100478T1/it unknown
- 2015-02-27 PT PT15736034T patent/PT3110837T/pt unknown
- 2015-02-27 JP JP2016553630A patent/JP6629747B2/ja active Active
- 2015-02-27 ES ES15736034T patent/ES2745335T3/es active Active
- 2015-02-27 EA EA201691691A patent/EA038000B1/ru unknown
- 2015-02-27 PL PL15736034T patent/PL3110837T3/pl unknown
- 2015-02-27 CR CR20160392A patent/CR20160392A/es unknown
- 2015-02-27 HU HUE19179287A patent/HUE055282T2/hu unknown
- 2015-02-27 MY MYPI2016001567A patent/MY181566A/en unknown
- 2015-02-27 ES ES19179287T patent/ES2885245T3/es active Active
- 2015-02-27 SM SM20190504T patent/SMT201900504T1/it unknown
- 2015-02-27 PE PE2016001528A patent/PE20161406A1/es not_active Application Discontinuation
- 2015-02-27 EP EP15736034.8A patent/EP3110837B1/en active Active
- 2015-02-27 EA EA202190727A patent/EA202190727A3/ru unknown
- 2015-02-27 PT PT191792878T patent/PT3608334T/pt unknown
- 2015-02-27 SI SI201530884T patent/SI3110837T1/sl unknown
- 2015-02-27 HR HRP20191511 patent/HRP20191511T1/hr unknown
- 2015-02-27 DK DK19179287.8T patent/DK3608334T3/da active
- 2015-02-27 WO PCT/IB2015/000999 patent/WO2015128746A2/en not_active Ceased
- 2015-02-27 LT LTEP19179287.8T patent/LT3608334T/lt unknown
- 2015-02-27 SI SI201531680T patent/SI3608334T1/sl unknown
- 2015-02-27 SG SG10202000537RA patent/SG10202000537RA/en unknown
- 2015-02-27 RS RSP20191144 patent/RS59344B1/sr unknown
- 2015-02-27 BR BR112016019868-9A patent/BR112016019868B1/pt not_active IP Right Cessation
- 2015-02-27 SG SG11201606863YA patent/SG11201606863YA/en unknown
- 2015-02-27 DK DK15736034.8T patent/DK3110837T3/da active
- 2015-02-27 AU AU2015221860A patent/AU2015221860B2/en active Active
- 2015-02-27 HU HUE15736034A patent/HUE045393T2/hu unknown
- 2015-02-27 LT LTEP15736034.8T patent/LT3110837T/lt unknown
- 2015-02-27 RS RS20211041A patent/RS62244B1/sr unknown
- 2015-02-27 EP EP19179287.8A patent/EP3608334B1/en active Active
- 2015-02-27 CA CA2940401A patent/CA2940401C/en active Active
- 2015-02-27 US US14/633,757 patent/US9290746B2/en active Active
-
2016
- 2016-03-21 US US15/075,457 patent/US9944910B2/en active Active
- 2016-08-23 DO DO2016000220A patent/DOP2016000220A/es unknown
- 2016-08-24 CL CL2016002142A patent/CL2016002142A1/es unknown
- 2016-08-25 PH PH12016501689A patent/PH12016501689A1/en unknown
- 2016-08-25 IL IL247481A patent/IL247481B/en active IP Right Grant
- 2016-08-26 NI NI201600127A patent/NI201600127A/es unknown
- 2016-08-26 SV SV2016005264A patent/SV2016005264A/es unknown
- 2016-09-26 ZA ZA2016/06655A patent/ZA201606655B/en unknown
-
2018
- 2018-04-16 US US15/954,021 patent/US10584318B2/en active Active
-
2019
- 2019-08-20 AU AU2019219743A patent/AU2019219743B2/en active Active
- 2019-09-11 CY CY20191100949T patent/CY1122644T1/el unknown
- 2019-09-25 ZA ZA2019/06304A patent/ZA201906304B/en unknown
- 2019-12-05 JP JP2019220178A patent/JP6896050B2/ja active Active
-
2020
- 2020-03-06 US US16/811,484 patent/US10907138B2/en active Active
- 2020-06-17 IL IL275435A patent/IL275435B/en unknown
-
2021
- 2021-08-17 HR HRP20211324TT patent/HRP20211324T1/hr unknown
- 2021-08-19 CY CY20211100743T patent/CY1124727T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10907138B2 (en) | TATk-CDKL5 fusion proteins, compositions, formulations, and use thereof | |
| US10751329B2 (en) | Treatment of CDKL5 disorders with GSK3β inhibitor tideglusib | |
| JP2017507655A5 (https=) | ||
| US20210268072A1 (en) | TATk-CDKL5 Fusion Proteins, Compositions, Formulations, and Use Thereof | |
| US9616138B1 (en) | Cargo carrying nanoparticles | |
| US11603394B2 (en) | Targeted effector proteins and uses thereof | |
| US20190225658A1 (en) | Peptibodies, compositions thereof, and methods of treating atrial fibrillation | |
| NZ749459A (en) | TATĸ-CDKL5 FUSION PROTEINS, COMPOSITIONS, FORMULATIONS, AND USE THEREOF | |
| HK1226745A1 (en) | Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof |